drugset / Trial / NCT07083401

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)

NCT07083401

Phase 1 Recruiting 40 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.

Timeline

Start
2025-07-05
Primary completion
2026-07-05
Completion
2026-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Metformin Small molecule 1000 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral

Indications